Review

D-Amino Acids and pLG72 in Alzheimer’s Disease and Schizophrenia

Yu-Jung Cheng¹,², Chieh-Hsin Lin³,⁴,⁵,⁶, * and Hsien-Yuan Lane³,⁴,⁷,⁸, *

¹ Department of Physical Therapy, Graduate Institute of Rehabilitation Science, China Medical University, Taichung 40402, Taiwan; chengyu@mail.cmu.edu.tw
² Department of Rehabilitation, China Medical University Hospital, Taichung 40402, Taiwan
³ Institute of Clinical Medical Science, China Medical University, Taichung 40402, Taiwan
⁴ Graduate Institute of Biomedical Sciences, China Medical University, Taichung 40402, Taiwan
⁵ Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
⁶ School of Medicine, Chang Gung University, Taoyuan 33302, Taiwan
⁷ Department of Psychiatry & Brain Disease Research Center, China Medical University Hospital, Taichung 40402, Taiwan
⁸ Department of Psychology, College of Medical and Health Sciences, Asia University, Taichung 41354, Taiwan
* Correspondence: cyndi36@gmail.com (C.-H.L.); hylane@gmail.com (H.-Y.L.);
Tel.: +886-7-7317123 (ext. 8753) (C.-H.L. & H.-Y.L.); Fax: +886-7-7326817 (C.-H.L. & H.-Y.L.)

Abstract: Numerous studies over the last several years have shown that D-amino acids, especially D-serine, have been related to brain and neurological disorders. Acknowledged neurological functions of D-amino acids include neurotransmission and learning and memory functions through modulating N-methyl-D-aspartate type glutamate receptors (NMDARs). Aberrant D-amino acids level and polymorphisms of genes related to D-amino acids metabolism are associated with neurodegenerative brain conditions. This review summarizes the roles of D-amino acids and pLG72, also known as D-amino acid oxidase activator, on two neurodegenerative disorders, schizophrenia and Alzheimer’s disease (AD). The scope includes the changes in D-amino acids levels, gene polymorphisms of G72 genomics, and the role of pLG72 on NMDARs and mitochondria in schizophrenia and AD. The clinical diagnostic value of D-amino acids and pLG72 and the therapeutic importance are also reviewed.

Keywords: Alzheimer’s disease; schizophrenia; D-amino acids; pLG72

1. Introduction

D-amino acids, in which the stereogenic carbon alpha of the amino group has a d-configuration, are agonists or co-agonists of N-methyl-D-aspartate type glutamate receptors (NMDARs). NMDARs are crucial in activity-dependent synaptic strength and structural changes related to long-term synaptic plasticity [1]. Thus, the levels of D-amino acids and their synthesis and degradation are linked to cognitive impairment, which is the core feature of schizophrenia and Alzheimer’s disease (AD). Indeed, studies show that the enzymes involved in D-amino acids metabolism correlate with AD and schizophrenia [2,3].

Schizophrenia and AD, the two most common neurological disorders, cause similar substantial cognitive and behavioral impairment. Although the pathophysiology of AD and schizophrenia are distinct, dysfunction of NMDARs transmission plays a critical role in their pathophysiology. An increasing number of studies focus on factors that regulate NMDAR activity in cellular and animal models of these two diseases. For instance, pLG72, also known as D-amino acid oxidase activator (DAOA) and able to modulate D-amino acid metabolism, is thought to be highly related to AD and schizophrenia pathogenesis. Polymorphisms in the G72 gene have been connected to behavioral and psychological symptoms in patients with AD [4] and schizophrenia [5]. In addition to regulating D-amino
acid levels, pLG72, localized in the mitochondria, is involved in the cellular oxidative stress defense system [6]. These pieces of evidence indicate that pLG72 plays a vital role in AD and schizophrenia and that targeting pLG72 could be a potential strategy for AD and schizophrenia treatment.

To elucidate the role of D-amino acids and pLG72 in AD, we first briefly summarize the metabolic pathways of D-amino acids and the changes of D-amino acid levels in AD and schizophrenia. Second, we discuss the known genetic variants in the G72 gene and the changes in pLG72 correlation in schizophrenia and AD. Third, we describe the possibility of therapeutically targeting the D-amino acids metabolism in schizophrenia and AD.

2. D-Amino Acids, D-Amino Acids Metabolism, and NMDAR

2.1. Source of D-Amino Acids

All amino acids except for glycine are stereoisomers. It is commonly assumed that L-amino acids are predominant in living organisms and that D-forms are primarily found in microorganisms and bacteria. Recent studies have shown that D-amino acids are also present in mammals. The sources of D-amino acids include microbial production, ingestion, and racemization. Endogenous D-amino acids are produced through racemization from their corresponding antipodes by racemases [7]. Hence, amino acid racemases play a crucial role in D-amino acids metabolism. Serine racemase (SR) and aspartate racemase are found in mammals. However, only serine racemases have been detected in human tissues [8–10]. Wolosker et al. cloned and purified SR, and they also found that SR is highly selective for L-serine [11]. In addition to D-serine synthesis, SR also participates in D-aspartate biosynthesis [12].

SR can convert D-serine from L-serine in the brain. Early studies have indicated that there are concentrations of D-serine and SR in astrocytes [11,13] and that this glia-derived D-serine modulates NMDA receptor activity and synaptic memory [14]. More recent studies have shown high amounts of SR and D-serine in primary neuronal cultures and neurons in vivo [15,16]. L-serine, produced in astrocytes, can be released by alanine, serine, cysteine, and threonine exchangers (ASCT1, SLC1a4) in exchange for D-serine and other amino acid substrates [17]. L-serine is further transported to neuronal cells by alanine-serine-cysteine-1 transporter (Asc-1, SLC7A10), which contributes to the uptake of L-serine in neurons [18]. The L-serine that is shuttled to neurons is converted to D-serine by SR. In the opposite direction, D-serine is released from neurons by an antiporter Asc-1 [19]. D-serine, taken up by astrocytes through the ASCT1 transporter, accumulates in the glial vesicles [17,20]. A serine shuttle model has been proposed to summarize the activity of L-serine, D-serine, Asc-1, and ASCT1 transporter [21] (Figure 1). In addition, primary astrocytes from ASCT1-KO mice, but not from ASCT2-KO mice, exhibited a reduced ability to uptake D-serine, L-serine, L-alanine, L-threonine, and glycine [17].

D-amino acids can be found extensively in foods and beverages, such as vegetables, fruits, wine, milk, beer, and fermented foods [22]. These acids are also generated during food processing; for example, bacteria and yeast produce D-amino acids during fermentation [23]. A study on vinegar found that the total D-amino acid level in lactic-fermented tomato vinegar was high, and lactic acid bacteria have a greater ability to produce D-amino acids than do yeast or acetic acid bacteria [24]. The alteration of D-amino acid concentration might depend on specific bacteria during red and white wine fermentation [25].
development of neurological disorders, such as Parkinson’s disease, AD, multiple sclerosis, schizophrenia, and autism [28–30]. By analyzing fecal samples from patients with AD and matched cognitively healthy controls, Zhung et al. found that gut microbiota composition was different between the two groups [31]. Similar to AD, studies showed a smaller subset of bacteria is different in schizophrenia patients compared with the control group [32]. Thus, one possibility is that gut bacteria from different microbiota environments generate different D-amino acids involved in the pathogenesis of AD and schizophrenia.

2.2. Elimination of D-Amino Acids and D-Amino Acid Oxidase

The flavin enzyme DAAO is found mainly in the kidney, liver, and brain of mammals [33,34]. By a reduction of its flavin adenine dinucleotide (FAD) coenzyme, DAAO oxidizes D-amino acids and produces imino acid. Afterward, the hydrolysis of imino acid causes the production of α-keto acid [35]. Mammalian DAAO enzyme activity has been identified in the rat brain, as well as in bovine and human nerve tissue [36,37]. DAAO activity is rare in the forebrain but high in the lower brain [38], and the localization of DAAO is inversely correlated with the presence of D-serine [39]. In addition, DAAO enzyme activity and mRNA are increased in the cerebellum after birth [40,41]. Cellular expression of DAAO is intense in glial cells, and histochemical studies observed intense DAAO activity in astrocytes, including those in Bergmann glial cells [36,38,42]. Immunohistochemistry staining and in situ hybridization have identified DAAO in glial cells in the brains of rats and humans [40,43,44].

After the administration of D-serine orally, plasma D-serine levels were significantly higher in DAAO knockout mice than in wild-type mice [45]. Using mutant ddY/DAAO-
mice lacking DAAO activity, Hashimoto et al. found that D-serine levels in the serum and cerebellum of mutant mice were much higher than in normal mice [46]. These findings indicate that DAAO is responsible for metabolizing D-serine. In addition, the catabolic enzyme D-aspartate oxidase (DASPO or DDO) regulates D-aspartate [47]. Mice lacking DDO had increased amounts of both D-aspartate and NMDA in all tissues [48]. Errico et al. investigated whether chronic treatment with D-aspartate and DDO gene deletion may trigger plastic modifications of neuronal cytoarchitecture in the prefrontal cortex and CA1 subfield on the hippocampus in mice [49]. Taken together, DAAO and DDO are both responsible for catabolizing D-serine and D-aspartate, which serve as co-agonists of NMDA receptors (NMDARs); this implies that DAAO and DDO are involved in neuronal function.

2.3. D-Amino Acids and NMDAR Function

Among all D-amino acids, D-aspartic acid, D-glutamate, D-alanine, and D-serine can modulate NMDARs directly by binding to glutamate or glycine binding sites [50]. After removing the Mg$^{2+}$ block and binding two agonists, glutamate and glycine, the NMDARs are activated and induce Na$^+$, K$^+$, and Ca$^{2+}$ currents [51–53]. Several studies indicate that Ca$^{2+}$ overload plays an essential role in NMDARs-mediated neurotoxicity [54–56]. The overactivation of extrasynaptic GluN2A-containing NMDARs might trigger glutamate excitotoxicity, which is correlated with cognitive decline and neurodegeneration in patients with AD. As NMDARs antagonist memantine reduces glutamate excitotoxicity, it provides both symptomatological and neuroprotective benefits in moderate to severe AD [57–60]. However, synaptic NMDARs are critical for neuronal survival [61,62]. Thus, the preservation of adequate NMDAR activity helps maintain neuronal survival when treating AD with NMDAR antagonists. Because NMDARs-mediated synaptic dysfunction affected by D-amino acids is a pathological change associated with AD, researchers have increasingly investigated the association between D-amino acids and AD. More and more studies focus on the alteration of D-amino acids and their metabolic pathways in AD.

2.4. Changes of D-Amino Acids, DAAO, and SR Levels in AD Patients

The changes in D-amino acid levels in patients with AD are well-studied; however, the results of these studies are controversial. It might have resulted from small sample size and different analytical methods. The methods to detect amino acid levels in some earlier articles cannot distinguish between free D-amino acids and D-amino acids derived from digested proteins [2]. Since D-serine is the main co-agonist of the NMDA receptor in the frontal brain [63–65], many studies have investigated the possible alteration of D-serine levels in AD. Madeira et al. observed that D-serine levels in the cerebrospinal fluid (CSF) of patients with a probable AD diagnosis were 5 times higher than CSF D-serine levels of controls [66]. In the same study, D-serine levels in postmortem hippocampal and cortical samples from AD patients were increased [66]. In a study on 376 individuals, Lin et al. found that D-serine levels and the D-serine to total serine ratio were significantly higher in patients with AD [67]. Another study from the same research team also revealed a significantly higher level of serum D-serine in patients with AD [68]. Compared with age-matched healthy controls, the serum D-serine levels and the D-serine to total serine ratios were significantly higher in individuals with AD progression [69]. However, several studies have revealed no statistically significant differences in the free D-serine levels in the frontal or parietal cortex between patients with AD and controls [70–73]. Nuzzo et al. analyzed the D-serine concentrations in the blood serum and CSF of patients representing the whole clinical spectrum of AD. They found that there was no alteration of D-serine levels in the blood serum or CSF. Moreover, there was no identified correlation between serum or CSF D-serine concentration and Mini-Mental State Examination scores [73]. Biemans et al. analyzed D-serine levels in the CSF of individuals with or without AD and found no notable difference between the two groups [74]. A systematic review and meta-analysis that included seven trials demonstrated that serum and CSF D-serine levels were significantly
higher in patients with AD than in controls [75]. Thus, D-serine levels are a potential biomarker for detecting AD.

The concentration of D-aspartate, another NMDA receptor co-agonist, was also quantified in the brains of individuals with and without AD. Aged-related accumulation of D-aspartate was found in the white matter but not the gray matter of normal brains [76]. D-aspartate levels were more than twice as high in the white matter of normal brains than in the white matter of AD brains, whereas the D-alanine concentration was more than twice as high in AD gray matter than in normal gray matter [77]. Using a new procedure to hydrolyze proteins without provoking racemization of amino acids, Fisher and colleagues found that D-aspartate concentration in both the gray matter and white matter of AD brains was significantly higher than that in healthy brains [78]. Higher levels of D-aspartic acid in the CSF of patients with AD have also been found compared with the ventricular CSF of healthy controls [79,80]. The level of D-alanine in the white and gray matter of AD brains was higher than in healthy brains, whereas total alanine was significantly lower in the gray matter of AD brains compared with healthy brains [81].

Research also suggested that there is a correlation between the changes in the levels of D-glutamate and AD. Cognitive decline in patients with AD is strongly correlated with decreased D-glutamate levels in blood [68,82,83]. Furthermore, lower hippocampal glutamate concentrations were found in patients with mild cognitive impairment (MCI) and AD compared with cognitively healthy older adult controls [84]. Vijayakumari and colleagues enrolled 15 patients with MCI and healthy controls and used functional magnetic resonance imaging (fMRI) to evaluate glutamate responses during working memory tasks. The results showed a significant increase in glutamate response during a working memory task in healthy participants but no observed significant changes in glutamate response in patients with MCI [85]. These studies indicate that dysregulated D-glutamate levels and glutamatergic neurotransmission may be associated with cognitive function in patients with AD or MCI.

Blood DAAO level could serve as a potential surrogate biomarker for AD. Our previous study examined serum DAAO levels and cognitive function in patients with MCI, mild AD, moderate to severe AD, and healthy older adults. The peripheral DAAO levels increased with the severity of cognitive deficits, and the Clinical Dementia Rating Scale (CDR) score was significantly associated with the DAAO level [68]. A similar increase in DAAO in the blood of patients with post-stroke dementia was noted, and the plasma DAAO levels were independently higher in subjects with dementia than subjects without dementia [86]. Treating with DAAO inhibitors, such as sodium benzoate, can ameliorate cognitive decline in patients with AD [87,88], indicating that over-activated DAAO plays a vital role in AD. In addition, several studies have demonstrated a direct association between SR and neurodegenerative diseases. Wu et al. observed that Aβ-peptide increased SR expression and D-serine concentration in cultured microglia. Compared with age-matched controls, the levels of SR mRNA were higher in the hippocampus of patients with AD [89]. In SR knockout mice, D-serine levels were reduced by approximately 90% in the forebrain, and NMDA- and Aβ- peptide-induced neurotoxicity was also significantly attenuated. These results suggest that SR is the primary enzyme for D-serine production, and D-serine may be involved in NMDA receptor-mediated neurotoxicity [90]. SR knockout mice exhibited impaired spatial memory and anxiety due to alteration in glutamatergic neurotransmission [91]. However, a recent study revealed that SR knockout mice, which had a weaker long-term potentiation (LTP) and a smaller increase in NMDA receptor potentials, had no deficits in spatial learning, reference memory, or cognitive flexibility. The significant increase in glycine levels [92] may explain the preservation of memory ability.

2.5. D-Amino Acids and NMDAR Function in Schizophrenia

In addition to the dopamine hypothesis, which is the main point on the pathophysiology of schizophrenia, more studies have shown that the dysfunction of NMDARs contributes to schizophrenia [93–95]. A large body of evidence has shown that there are al-
tered D-serine levels in patients with schizophrenia. Bendikov et al. monitored the D-serine levels in CSF and SR expression in postmortem brains of schizophrenic patients. The study showed that the D-serine levels and D/L-serine ratio in CSF decreased by 25%, and SR protein levels in the frontal cortex and hippocampal in postmortem brain of schizophrenic patients were also reduced [96]. Hashimoto et al. reported a reduced D-serine to total serine ratio in the CSF of drug-naïve schizophrenic patients [97]. However, another study had revealed no statistically significant differences in the D-serine levels in CSF between patients with schizophrenia and control [98]. In the same study, the levels of L-serine, L-glutamine, and L-glutamate in CSF were unchanged [96]. Other studies also showed that serum D-serine levels in the patients with schizophrenia were significantly lower than in the healthy controls [99,100]. A systematic review summarized six studies, and results from the meta-analysis showed that patients with schizophrenia had lower serum D-serine levels than healthy controls [101]. In summary, generally increased D-serine level was observed in AD and decreased D-serine was reported in schizophrenia patients (see Table 1).

Since Aβ can induce SR expression and D-serine release in microglia [89], it is not surprising that the D-serine level increases along with AD progression. In addition, the racemization of protein-bound amino acids is significant in protein aging and aggregation, which contributes to neurodegeneration [102]. The Aβ1-40, racemized at Ser26, is soluble and susceptible to proteolysis, which converts into toxic fragments [103], and this racemized amyloid-β is associated with AD pathogenesis [104]. Hence, the D-serine from proteolytic Aβ might also contribute to the elevated D-serine levels in AD patients. Different from AD, there is no evidence showing that Aβ levels are different in patients with schizophrenia than in controls, and the excessiveness of Aβ is not associated with cognitive impairment in schizophrenia [105]. Thus, the differential pattern of D-serine levels between AD and schizophrenia might have resulted from the accumulation and proteolysis of Aβ.

Interestingly, a study monitoring changes in glycine, L-serine, and D-serine levels in the plasma of schizophrenic patients during treatment showed that there was a significant increase in D-serine levels along with an improvement in clinical symptoms [106]. Thus, D-serine levels are a potential “clinical status” biomarker in patients with acute schizophrenia. Moreover, clinical trials have shown that D-serine treatment significantly improves positive, negative, and cognitive symptoms in patients with schizophrenia and bipolar disorder [107]. In addition, several studies report increased mRNA, protein, or enzyme activity of DAAO in subjects with schizophrenia [40,108–110]. Verral et al. analyzed different brain regions in autopsies of schizophrenic patients, and they found DAAO increased in the cerebellum, whereas SR mRNA increased in the dorsolateral prefrontal cortex [40]. The distinct expression pattern in different brain regions of schizophrenic patients implies that the regulation of D-serine by DAAO/SR needs further investigation.

The concentration of D-aspartate, another NMDA receptor co-agonist, was found reduced in the prefrontal cortex and striatum in schizophrenic patients [111]. The concentration of D-aspartate is markedly high in the embryonic brain and then rapidly decreases after birth due to DDO [112–114]. In DDO knockout mice, increased D-aspartate attenuates phencyclidine-induced schizophrenia-like behaviors [115]. The same group reported that D-aspartate not only can increase in vivo NMDAR activity but also can attenuate schizophrenia-like symptoms induced by amphetamine and MK-801 [116]. Consistent with the animal model results, there is a link between low D-aspartate levels and enhanced DDO activity in the dorsolateral prefrontal cortex of schizophrenic patients [117]. However, exposure to excessive D-aspartate in DDO knockout mice facilitated age-dependent brain neurodegeneration processes, which indicated the excitotoxicity of NMDA receptors [118]. Keller et al. analyzed the mRNA levels and DNA methylation status of SR, DAAO, G72, and DDO in postmortem brain samples from patients with schizophrenia and controls [119]. They found that the DDO methylation and expression were lower in the cerebellum compared with the hippocampus and dorsolateral prefrontal cortex. Although there was no difference between healthy controls and schizophrenia patients, the finding from DNA methylation is consistent with the DDO gene activity in the cerebellum. Moreover, a
single nucleotide polymorphism (SNP) rs3757351 on the DDO gene is also associated with reduced DDO expression in vivo prefrontal phenotypes relevant to schizophrenia and greater prefrontal gray matter volume [49]. These results implicated the dysregulation of D-aspartate as perhaps playing an important role in schizophrenia [120].

Glutamate is the primary excitatory neurotransmitter, and glutamatergic theory is one of the most influential hypotheses in schizophrenia. Some studies found serum glutamate level was significantly higher in schizophrenia patients [121–123]. However, the plasma glutamate level is not correlated with its level in the brain because glutamate is synthesized too in the central nervous system [124,125]. Although D-glutamate is primarily degraded by DDO in eukaryotic organisms [126], D-aspartate, but not D-glutamate, was significantly increased in DDO knockout mice brain, which suggested that DDO mainly catalyzes D-aspartate, not D-glutamate [127]. Ariyoshi and co-authors identified a novel mammalian mitochondrial protein 9030617O03Rik, a D-glutamate cyclase that converts D-glutamate to 5-oxo-D-proline [128]. Unlike AD, there is no evidence showing a correlation between D-glutamate cyclase and schizophrenia.

As mentioned, NMDARs hypofunction contributes to schizophrenia, and d-serine is the primary NMDAR co-agonist, and it is synthesized by SR. It is not surprising that there is an association between SR activity and schizophrenia pathophysiology. Labrie et al. induced SR gene mutation and generated mice with low SR activity and S-serine level. These mice displayed behaviors relevant to schizophrenia, including impairments in prepulse inhibition, sociability, and spatial discrimination [129]. Basu and co-authors generated SR knockout mice, but SR−/− mice exhibited intact prepulse inhibition (PPI) response, which was impaired in schizophrenic patients at the acute stage [91]. Although D-serine levels were reduced by approximately 90% in SR knockout mice, the intact PPI response might have resulted from other NMDARs co-agonist glycine. Regardless of the behavioral phenotype, SR knockout mice showed some pathologic features of schizophrenia, such as loss of cortical gray matter, reduction of cortical glutamatergic synapses, downregulation of parvalbumin-positive cortical GABAergic neurons, and cognitive development impairments [130–132]. Recent studies show that dysregulation of SR/Disrupted-In-Schizophrenia-1 (DISC1) also contributes to schizophrenia. DISC1 binds to SR, and disruption of SR/DISC1 complex caused schizophrenia-like behavior through D-serine depletion [133,134]. Moreover, few SR genetic variants associated with schizophrenia have been identified in humans [129,135]. Later, a genome-wide association study of 36,989 patients with schizophrenia and 113,075 controls also showed the SNP rs4523957 of the SR gene is one of the gene variants associated with schizophrenia [136], and rs4523957 may be associated with some phenotypes of schizophrenia in the Han Chinese population [137].

| Sample/Area | AD | Schizophrenia |
|-------------|----|--------------|
| Human autopsy/ Frontal cortex | ↔ [71] | - |
| Postmortem human sample/ Superior frontal cortex | ↔ [73] | - |
| Postmortem human sample/ Parietal cortex | ↑ [66] | ↔ [96] |
| Postmortem human sample/ Hippocampus | ↑ [66] | - |
| Amyloid-β injected mice/ Hippocampus | ↑ [66] | - |
| Human CSF | ↔ [73], ↑ [66] | ↓ [96], ↔ [97,98] |
| Human Blood (serum/plasma) | ↔ [73] ↑ [2,67] | ↓ [99,100] |

↑: significantly increased, ↓ significantly decreased, ↔ no significant difference.
3. D-Amino Acids Oxidase Activator, G72

3.1. Biological Function of G72 and the Possible Role of G72 in AD

G72 is a primate-specific gene located in the 13q33.2 chromosomal region and encodes a protein with 153 amino acid residues. In 2002, Chumakov et al. first described strong associations between schizophrenia and SNPs of G72 [138]. This study also reveals that the pLG72 protein binds to DAAO through the yeast two-hybrid technique, and the in vitro result shows that pLG72 protein can activate DAAO. Reverse transcription-polymerase chain reaction (RT-PCR) and real-time PCR results show that G72 expression is only detected in human testis and brain [139]. In G72 transgenic mice, expression of pLG72 in the cerebellum, hippocampus, cortex in the brain, heart, testis, and spleen in peripheral tissue was found [140,141]. Transgenic mice with an overexpressed human G72/G30 genomic region show behavioral phenotypes related to schizophrenia and depression [141], which indicates that the G72 gene does play a role in modulating behaviors.

There are three possible mechanisms of how pLG72 modulates behaviors. The first one is through pLG72–DAAO–NMDAR; second, it can modulate mitochondrial function; and last, it can induce oxidative stress. Although Chumakov et al. proposed that G72 can bind DAAO and serve as a DAAO activator, the effects of pLG72 in regulating DAAO activity are still inconclusive. According to a detailed functional analysis, the inhibitory effects of pLG72 on DAAO have been reviewed comprehensively [6]. The protein–protein interaction of DAAO and pLG72 was confirmed at the in vitro and cellular level by several different groups [44,138,142–144]. Yeast two-hybrid experiments demonstrated that pLG72 interacts with DAAO in vitro and that there was an increase in the activity of DAAO in the presence of pLG72 [138,145]. Immunohistochemical staining and immunoprecipitation showed that there was an expression and interaction of DAAO and pLG72 in the human cortex [44]. Nevertheless, co-expression of pLG72 with DAAO in glioblastoma cells abolishes the effects of DAAO, which indicates that pLG72 may also act as a repressor of DAAO [44]. The same group reported that pLG72 briefly interacted with DAAO in the cytosol and negatively affected the half-life of DAAO [146]. Another group also failed to repeat the DAAO activator function of pLG72 in Gos7 and U251 glioblastoma cells [147]. Sacchi and co-authors tested the DAAO modulation functions of wild-type pLG72, R30K variant, and K62E variant. They found that pLG72 variants, including wild-type pLG72, actually inhibit human DAAO, which leads to increasing D/ D+L-serine levels [142]. Through pLG72-directed DAAO activity assay, Terry-Lorenzo et al. found that pLG72 can dose-dependently inhibit DAAO [148]. Testing in various human cell lines suggested that the effects of pLG72 on DAAO activity are cell type-dependent [144]. As mentioned, DAAO modulates D-serine levels, which regulate NMDAR biological function. Thus, the interaction between pLG72 and DAAO links abnormal D-serine levels and NMDAR dysfunction-related neurological disorders, including AD [2].

In addition to modulating DAAO activity, there was also a report regarding G72 affecting mitochondrial function. The N-terminal of pLG72 contains a mitochondrial translocation sequence, and immunostaining results show that pLG72 is mainly localized in mitochondria [147]. Increased pLG72 proteins induced mitochondrial fragmentation without inducing apoptosis in the Gos7 cell line and primary neurons. Moreover, transfection with pLG72 in primary hippocampal neurons changed mitochondrial morphology and dendritic branching [147]. Interestingly, overexpression of pLG72 affected several mitochondrial-related gene expressions and increased reactive oxygen species (ROS) in U87 glioblastoma cells [149]. pLG72 transgenic mice show schizophrenia-relevant behaviors, mitochondrial dysfunction, and higher ROS production [150]. Since ROS, generated by mitochondria, participates in many neurodegenerative diseases, there has been a link between pLG72-associated ROS production and AD. Treating with antioxidant N-acetyl cysteine can improve the cognitive deficits of pLG72 transgenic mice [150]. Through the yeast-two hybrid system, the same group reported that mitochondrial methionine sulfoxide S reductase B2 (MSRB2) is the binding partner of pLG72 [151]. Increasing pLG72 protein expression induces mitochondrial oxidative stress by altering MSRB2 function.
In addition to MSRB2, pLG72 was reported to bind Flavin mononucleotide (FMN) and modulate FMN-containing oxidoreductase activity in the respiratory complex I [44,142]. Interestingly, MSRB2-mediated antioxidative activity can reduce amyloidogenesis and Tau phosphorylation in the AD mice model [152]. These results imply that the role of pLG72 on mitochondria dysfunction may enhance AD pathogenesis (Figure 2).

Figure 2. The DAAO–pLG72 interaction in D-serine degradation and mitochondria stress. D-serine is degraded by DAAO in astrocytes. pLG72, when on the mitochondrial outer membrane, can bind and inhibit DAAO. Overexpressed pLG72 on mitochondria also induces mitochondria fragmentation and oxidative stress (created with BioRender.com accessed on 25 September 2021).

3.2. Role of G72 in Schizophrenia

The association of neurological disorders and G72 gene variations was first discovered in schizophrenia and psychiatric conditions [153–156]. In the paper reporting the discovery of the G72 gene, Chumakov et al. suggested a possible link between pLG72 and schizophrenia due to its DAAO modulation function [138]. Although Sacchi et al. showed contradicting results to Chumakov’s finding and demonstrated that pLG72 acts as a negative effector of human DAAO, they proposed that increased DAAO and decreased pLG72 expression might lower d-serine concentration and be involved in schizophrenia susceptibility [44]. Ishiwata’s group showed a significant positive correlation between plasma G72 levels and positive symptoms of schizophrenia [157]. However, a tendency toward overexpression of G72 mRNA and protein in the brains of schizophrenic patients compared with healthy controls was observed [158]. Similar to the brain findings, a significant elevation of G72 protein in the plasma of schizophrenic patients was detected compared with healthy controls [159]. While the pLG72 R30K, the best-known SNP rs2391191 in G72, has a shorter half-life than wild-type pLG72, the overexpressed pLG72 in schizophrenia patients might be due to the compensatory result.

Plenty of studies have analyzed genetic variants and tried to link these markers with schizophrenia. SNP-based studies showed that several G72 gene variants were associated with schizophrenia in different populations [138,158,160–165]. However, some SNPs (rs3916965, rs1341402, rs2391191, rs778293, and rs3918342) show controversial associations in different studies, possibly resulting from different populations [139]. Lin et al. analyzed the G72 SNPs and G72 protein levels from schizophrenia patients and healthy controls with
leveraging computational artificial intelligence and machine learning. They found G72 rs1421292 plus G72 protein seemed to be the best model for schizophrenia susceptibility [5]. SNP rs2391191 and rs9558562 induce R30K and K62E substitution, R30K pLG72 has a shorter half-life, and K62E has higher DAAO inhibition than wild type [6]. Moreover, schizophrenic patients who carried the rs2391191 variant appeared to have a significantly thinner cortex, which indicated the pathophysiological role of pLG72 in schizophrenia [166]. Hall et al. analyzed the brain activation with functional magnetic resonance imaging in subjects carrying two G72 SNPs, rs918342 and rs1421292. Their results showed differences in the activation of the left hippocampus and parahippocampus between G72 genotype groups, which indicated that genetic variation of G72 may affect hippocampal complex and prefrontal cortex function [167].

### 3.3. Association of G72 with AD

Similar to schizophrenia, genetic variation of the G72 gene was found to be connected with AD. After screening 185 AD patients for SNP, one SNP—rs2153674—was associated with more frequent and severe delusions assessed with the Neuropsychiatric Inventory [4]. Arcos-Burgos and his team analyzed the world’s largest multigenerational pedigree with early onset of AD, carrying the PSEN1 p.Glu280Ala mutation. With pooling/bootstrap-based genome-wide association studies (pbGWAS), they first reported a novel locus including G72 (rs778296) that is significantly associated with the early onset of AD [168]. Later they found that an exonic missense mutation of G72 (rs2391191) was also significantly associated with the age of onset by whole-exome genotyping of sixty individuals [169]. In addition, an association between G72 gene variations and some AD- or dementia-related psychological disorders, including panic disorder [170], bipolar disorder, [156], persecutory delusions [171], and frontal lobe volume changes, was observed [172]. Results of GWAS have shown that AD and schizophrenia share similar physical phenotypes through standard GWAS signals [173] and that G72 provides a good example of the links between these two diseases.

For protein expression level, a postmortem study showed that pLG72 protein expression levels at different ages was statistically significantly different in the brainstem [174]. Lin et al. first showed that the pLG72 level in plasma is about 2-fold higher in schizophrenic patients than in control subjects [159]. The same group further measured the pLG72 protein levels in the plasma of 376 participants who evaluated the severity of cognitive deficit through the Clinical Dementia Rating Scale. In patients with MCI, mild and moderate AD, the levels of pLG72 were increased compared with healthy subjects. However, pLG72 levels in severe AD were not significantly different [67]. These findings suggest that pLG72 may not be suitable as a biomarker for late AD. Moreover, the D-serine level and D- to total serine ratio in MCI and AD patients were significantly higher than in the healthy control. These findings suggest that pLG72-mediated DAAO modulation might contribute to NMDAR dysfunction and AD progression.

Several studies that analyzed G72 gene variants showed a genetic association between AD and schizophrenia risk. Table 2 summarizes the genetic studies that had analyzed both disease groups. As shown in Table 2, one SNP, rs2391191, is related to an increase in the risk of AD and schizophrenia. According to the available results, there is an increased pLG72 expression in AD and schizophrenic patients (Table 3).

| Polymorphisms | Position | Schizophrenia | AD | Global MAF [175] | MAF in Schizophrenia | MAF in AD |
|---------------|----------|---------------|---|------------------|----------------------|----------|
| M15 rs2391191 (G>A/G>C) | chr13:104917447 | + [138,161,162,164] | + [169] | 0.370658 (A) | 0.35 (A) [138] | N/A |
| rs2153674 (C>A/G>C>T) | chr13:105478789 | – [176] | + [4] | 0.47364 (C) | N/A | 0.44 (C) [4] |
| M19 rs778294 (C>A/C>T) | chr13:104940236 | – [160] | + [169] | 0.281331 (T) | 0.253 (T) [160] | 0.3 (A) [4] |

+ represents significant association, and − represents no correlation.
### Table 3. Changes in pLG72 levels in AD and schizophrenia.

| Sample/Area                                    | MCI | AD          | Schizophrenia |
|-----------------------------------------------|-----|-------------|---------------|
| Postmortem human sample/                      | -   | -           | ↑ [158]       |
| dorsolateral prefrontal cortex                |     |             |               |
| Human CSF                                      | -   | ↑ [67]      | ↔ [157]       |
| Human Blood (serum/plasma)                    | ↑ [67] | ↑ [67] (mild and moderate AD), ↓ [67] (severe AD) | ↑ [159], ↔ [157] |

↑: significantly increased, ↓: significantly decreased, ↔: no significant difference.

### 4. Therapeutic Targeting to D-Amino Acids Metabolic Pathways in AD and Schizophrenia

Given the contribution of NMDARs to learning and memory, it is unsurprising that medical researchers have attempted to improve cognitive function by enhancing NMDA receptor activity both in AD and schizophrenia. Although D-serine levels in brain tissues and the blood are not similar, therapeutic strategies targeting the D-amino acids metabolic pathway can improve cognition symptoms in both diseases. Both glycine and D-serine can bind to the glycine modulatory site of the NMDA receptor; however, D-serine has more significant potential. The median effective dose 50 (ED50) for D-serine activation of NMDARs is 3 to 4 times lower than glycine [178]. The extracellular concentration of free D-serine in the frontal cortex is sufficient to saturate the glycine binding site on the NMDA receptor in rodent brains [178]. After intravenous administration, D-serine had a higher uptake than had L-serine in rat brains [179]. A single systemic administration of D-serine resulted in the prolonged elevation of D-serine levels in the rat cortex and hippocampus [180], which are the affected brain regions in AD. In rats, an fMRI study found that intraperitoneal D-serine administration increased NMDA receptor activation in the hippocampus [181]. Moreover, D-serine treatment can enhance social memory in rats [182]. Both pre- and post-training treatment with D-serine improved recognition memory in mice [183]. These studies imply that increasing D-serine levels in patients with AD and schizophrenia might have positive effects.

As mentioned, the hypofunction of NMDARs plays a crucial role in schizophrenia, and D-serine is a potent co-agonist of NMDARs. Hence, it is not surprising that D-serine was tested to treat schizophrenia. Several studies have shown D-serine supplements did improve psychological symptoms of schizophrenia [107,184,185]. In addition to enhancing NMDARs activity by administrating D-serine directly, increasing endogenous D-serine concentration by inhibiting DAAO also resulted in therapeutic improvement. Sodium benzoate, a specific DAAO inhibitor, can increase D-serine level, reduce symptoms, and improve neurocognition in patients with chronic schizophrenia [186]. The same group showed that combined GlyT1 inhibitor sarcosine and sodium benzoate, not sarcosine, can improve cognition and global functioning of schizophrenic patients [187]. Moreover, similar beneficial effects of sodium benzoate on clozapine-resistant schizophrenic patients were also noted. Clozapine combined with sodium benzoate can improve the therapeutic effects of clozapine on symptomatology [188].

Due to the hypothesis in AD pathogenesis that excessive D-serine may induce NMDARs over-activation and neurotoxicity, there is no clinical trial testing the efficacy of D-serine on AD. However, D-serine treatment can enhance neurogenesis and the survival of newborn neurons [189], which implies that increasing D-serine levels might benefit AD. Indeed, reducing D-serine degradation by blocking DAAO activity, thereby enhancing NMDA receptor activity, can prevent neuronal cell death [190]. Sodium benzoate is a selective inhibitor of DAAO, which can effectively reduce DAAO-mediated reactions in a dose-dependent manner [191–193]. In a 5XFAD transgenic mouse model of AD, oral feeding of sodium benzoate suppressed the activation of p21rac, oxidative stress, neuronal...
apoptosis, glial activation, and Aβ deposits in the hippocampus [194]. In addition, several clinical trials have evaluated the efficacy of sodium benzoate in patients with MCI and AD. A randomized, double-blind, placebo-controlled trial of patients with amnestic MCI and mild AD showed that 24 weeks of daily treatment with sodium benzoate improved cognitive and overall function [87]. Another double-blind, 6-week trial demonstrated that high-dose sodium benzoate treatment did not improve behavioral and psychological symptoms of dementia (BPSD) [195]. However, after improving the treatment with a precision medicine approach, sodium benzoate reduced DAAO levels and attenuated D-serine declines in patients with BPSD. Moreover, there is a correlation between cognitive improvement after sodium benzoate treatment and decreased DAAO levels [88]. These studies indicate that sodium benzoate may have the potential to improve cognitive function in early-phase AD. Notably, a second analysis of the same cohort showed that sodium benzoate treatment was more effective in women than in men for improving cognitive function [196], implying that sex hormones may play a role.

As mentioned in the previous section, serum D-serine levels in the early phases of AD can be a biomarker for clinical status. Since increased D-amino acids levels might have resulted from Aβ stimulation and digested products of Aβ peptides, the changes of D-amino acids levels after treatment are important. Aducanumab, the newly FDA-approved drug for AD, is designed to target oligomers and fibrils of Aβ [197]. The intravenous administration of aducanumab can reduce brain Aβ, which might be through increasing microglia-mediated phagocytosis of antibody–Aβ complexes [198]. Although clearance of racemized Aβ may reduce D-amino acids levels, the activation of microglia could also induce SR expression and release D-serine. Thus, it would be worth monitoring the changes in D-amino acid levels in patients treated with aducanumab.

5. Conclusions

Schizophrenia and AD, two neurological disorders, share psychiatric symptoms that result from NMDARs dysregulation. Among the regulators of NMDARs, more and more evidence shows that D-amino acids contribute to the pathogenesis of AD and schizophrenia. Thus, the genes/proteins that participate in D-amino acids metabolism serve as targets for treating schizophrenia and AD. pLG72 not only modulates DAAO but also affects mitochondria-related oxidative stress. The G72 gene polymorphisms and pLG72 protein express similar patterns in schizophrenia and AD. Moreover, changes in D-amino acids, DAAO, and G72 have been found in patients with schizophrenia and AD-related cognitive dysfunction, demonstrating their potential as therapeutic targets for both diseases. Indeed, the modulation of DAAO activity by DAAO inhibitors has shown effectiveness in several clinical trials on both diseases. However, more investigation into the efficacy and safety of treatments based on D-amino acid modulation in AD and schizophrenia is necessary.

Author Contributions: Conceptualization: C.-H.L. and H.-Y.L.; writing, Y.-J.C. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the National Health Research Institutes, Taiwan (NHRI-EX109-10731Ni; NHRI-EX110-10816NC), the Ministry of Science and Technology in Taiwan (MOST 108-2410-H-039-009-MY2; 109-2628-B-182A-002; 109-2314-B-039-039-MY3; 109-2314-B-039-001; 110-2314-B-182A-048; 110-2622-B039-001), and Chang Gung Memorial Hospital, Taiwan (CMRPG8G1391, CMRPG8K1162, CMRPG8K1461), and China Medical University (CMU107-S-25).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Acknowledgments: All figures were created with BioRender. We thank Mary Audrey D. Viloria for English language editing.

Conflicts of Interest: The authors declare no conflict of interest.
Glossary

Asc-1 alanine-serine-cysteine-1 transporter
DISC1 Disrupted-In-Schizophrenia-1
FMN flavin mononucleotide
fMRI functional magnetic resonance imaging
NMDAR N-methyl-D-aspartate type glutamate receptors
AD Alzheimer’s disease
ASCT1 alanine, serine, cysteine, and threonine exchangers
BPSD behavioral and psychological symptoms of dementia
CSF cerebrospinal fluid
DAO D-amino acids oxidase
DDO D-aspartate oxidase
ED50 effective dose 50
FAD flavin adenine dinucleotide
MSRB2 mitochondrial methionine sulfoxide S reductase B2
pbGWAS pooling/bootstrap-based genome-wide association studies
PPI prepulse inhibition
ROS reactive oxygen species
RT-PCR reverse transcription-polymerase chain reaction
SNP single nucleotide polymorphism
SR serine racemase

References

1. Gnegy, M.E. Ca2+/calmodulin signaling in NMDA-induced synaptic plasticity. Crit. Rev. Neurobiol. 2000, 14, 91–129. [CrossRef] [PubMed]
2. Piubelli, L.; Murtas, G.; Rabattoni, V.; Pollegioni, L. The Role of D-Amino Acids in Alzheimer’s Disease. J. Alzheimers Dis. 2021, 80, 475–492. [CrossRef] [PubMed]
3. Seckler, J.M.; Lewis, S.J. Advances in D-Amino Acids in Neurological Research. Int. J. Mol. Sci. 2020, 21, 7325. [CrossRef] [PubMed]
4. Di Maria, E.; Bonvicini, C.; Bonomini, C.; Alberici, A.; Zanetti, O.; Gennarelli, M. Genetic variation in the G720/G30 gene locus (DAOA) influences the occurrence of psychotic symptoms in patients with Alzheimer’s disease. J. Alzheimers Dis. 2009, 18, 953–960. [CrossRef] [PubMed]
5. Lin, E.; Lin, C.H.; Lai, Y.L.; Huang, C.H.; Huang, Y.J.; Lane, H.Y. Combination of G72 Genetic Variation and G72 Protein Level to Detect Schizophrenia: Machine Learning Approaches. Front. Psychiatry 2018, 9, 566. [CrossRef]
6. Pollegioni, L.; Piubelli, L.; Molla, G.; Rosini, E. D-Amino Acid Oxidase-pLG72 Interaction and D-Serine Modulation. Front. Mol. Biosci. 2018, 5, 3. [CrossRef] [PubMed]
7. Yoshimura, T.; Esak, N. Amino acid racemases: Functions and mechanisms. J. Biosci. Bioeng. 2003, 96, 103–109. [CrossRef]
8. Wolosker, H.; Blackshaw, S.; Snyder, S.H. Serine racemase: A glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc. Natl. Acad. Sci. USA 1999, 96, 13409–13414. [CrossRef]
9. Foltyn, V.N.; Bendikov, I.; De Miranda, J.; Panizzutti, R.; Dumin, E.; Shleper, M.; Li, P.; Toney, M.D.; Kartvelishvily, E.; Wolosker, H. Serine racemase modulates intracellular D-serine levels through an alpha, beta-elimination activity. J. Biol. Chem. 2005, 280, 1754–1763. [CrossRef]
10. Raboni, S.; Marchetti, M.; Faggiano, S.; Campanini, B.; Bruno, S.; Marchesani, F.; Margiotta, M.; Mozzarelli, A. The Energy Landscape of Human Serine Racemase. Front. Mol. Biosci. 2018, 5, 112. [CrossRef]
11. Wolosker, H.; Sheth, K.N.; Takahashi, M.; Motzet, J.P.; Brady, R.O., Jr.; Ferris, C.D.; Snyder, S.H. Purification of serine racemase: Biosynthesis of the neuromodulator D-serine. Proc. Natl. Acad. Sci. USA 1999, 96, 721–725. [CrossRef] [PubMed]
12. Ito, T.; Hayashida, M.; Kobayashi, S.; Muto, N.; Hayashi, A.; Yoshimura, T.; Mori, H. Serine racemase is involved in d-aspartate biosynthesis. J. Biochem. 2016, 160, 345–353. [CrossRef]
13. Schell, M.J.; Brady, R.O., Jr.; Molliver, M.E.; Snyder, S.H. D-serine as a neuromodulator: Regional and developmental localizations in rat brain glia resemble NMDA receptors. J. Neurosci. 1997, 17, 1604–1615. [CrossRef] [PubMed]
14. Panatier, A.; Theodosis, D.T.; Mothet, J.P.; Touquet, B.; Pollegioni, L.; Poulain, D.A.; Oliet, S.H. Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell 2006, 125, 775–784. [CrossRef] [PubMed]
15. Kartvelishvily, E.; Shleper, M.; Balan, L.; Dumin, E.; Wolosker, H. Neuron-derived D-serine release provides a novel means to activate N-methyl-D-aspartate receptors. J. Biol. Chem. 2006, 281, 14151–14162. [CrossRef] [PubMed]
16. Miya, K.; Inoue, R.; Takata, Y.; Abe, M.; Natsume, R.; Sakimura, K.; Hongou, K.; Miyawaki, T.; Mori, H. Serine racemase is predominantly localized in neurons in mouse brain. J. Comp. Neurol. 2008, 510, 641–654. [CrossRef]
17. Kaplan, E.; Zubeidat, S.; Radziszhevsky, I.; Valenta, A.C.; Rechnitz, O.; Sason, H.; Sajrawi, C.; Bodner, O.; Konno, K.; Esaki, K.; et al. ASCT1 (Slc1a4) transporter is a physiologic regulator of brain d-serine and neurodevelopment. Proc. Natl. Acad. Sci. USA 2018, 115, 9628–9633. [CrossRef]

18. Rutter, A.R.; Fradley, R.L.; Garrett, E.M.; Chapman, K.L.; Lawrence, J.M.; Rosahl, T.W.; Patel, S. Evidence from gene knockout studies implicates Asc-1 as the primary transporter mediating d-serine reuptake in the mouse CNS. Eur. J. Neurosci. 2007, 25, 1757–1766. [CrossRef]

19. Rosenberg, D.; Artoul, S.; Segal, A.C.; Kolodney, G.; Radziszhevsky, I.; Dikopoltsev, E.; Foltyn, V.N.; Inoue, R.; Mori, H.; Billard, J.M.; et al. Neuronal D-serine and glycine release via the Asc-1 transporter regulates NMDA-receptor-dependent synaptic activity. J. Neurosci. 2013, 33, 3533–3544. [CrossRef]

20. Ribeiro, C.S.; Reis, M.; Panizzutti, R.; de Miranda, J.; Wolosker, H. Glial transport of the neuromodulator D-serine. Brain Res. 2002, 929, 202–209. [CrossRef]

21. Wolosker, H. Serine racemase and the serine shuttle between neurons and astrocytes. Biochim. Biophys. Acta 2011, 1814, 1558–1566. [CrossRef]

22. Mutaguchi, Y.; Kobayashi, J.; Oikawa, T.; Ohshima, T. D-Amino Acids: Physiology, Metabolism, and Application; Springer: Berlin/Heidelberg, Germany, 2016.

23. Gobbetti, M.; Simonetti, M.S.; Rossi, J.; Cossignani, L.; Corsetti, A.; Damiani, P. Free D-Amino-Acid and L-Amino-Acid Evolution during Sourdough Fermentation and Baking. J. Food Sci. 1994, 59, 881–884. [CrossRef]

24. Mutaguchi, Y.; Ohmori, T.; Akano, H.; Doi, K.; Ohshima, T. Distribution of D-amino acids in vinegars and involvement of lactic acid bacteria in the production of D-amino acids. SpringerPlus 2013, 2, 691. [CrossRef]

25. Kato, S.; Ishihara, T.; Hemmi, H.; Kobayashi, H.; Yoshimura, T. Alterations in D-amino acid concentrations and microbial community structures during the fermentation of red and white wines. J. Biosci. Bioeng. 2011, 111, 104–108. [CrossRef]

26. Sasabe, J.; Miyoshi, Y.; Rakoff-Nahoum, S.; Zhang, T.; Mita, M.; Davis, B.M.; Hamase, K.; Waldor, M.K. Interplay between microbial d-amino acids and host d-amino acid oxidase modifies murine mucosal defence and gut microbiota. Nat. Microbiol. 2016, 1, 1625. [CrossRef]

27. Aliashkevich, A.; Alvarez, L.; Cava, F. New Insights Into the Mechanisms and Biological Roles of D-Amino Acids in Complex Eco-Systems. Front. Microbiol. 2018, 9, 683. [CrossRef] [PubMed]

28. Kowalski, K.; Mulak, A. Brain-Gut-Microbiota Axis in Alzheimer’s Disease. J. Neurogastroenterol. Motil. 2019, 25, 48–60. [CrossRef] [PubMed]

29. Ghaisas, S.; Maher, J.; Kanthasamy, A. Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. Pharmacol. Ther. 2016, 158, 52–62. [CrossRef] [PubMed]

30. Quigley, E.M.M. Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. Curr. Neurol. Neurosci. Rep. 2017, 17, 94. [CrossRef] [PubMed]

31. Zhuang, Z.Q.; Shen, L.L.; Li, W.W.; Fu, X.; Zeng, F.; Gui, L.; Lu, Y.; Cai, M.; Zhu, C.; Tan, Y.L.; et al. Gut Microbiota is Altered in Patients with Alzheimer’s Disease. J. Alzheimers Dis. 2018, 63, 1337–1346. [CrossRef]

32. Akhondzadeh, S. Microbiome and Schizophrenia. Avicenna J. Med. Biotechnol. 2019, 11, 269. [PubMed]

33. Krebs, H.A. Metabolism of amino-acids: Deamination of amino-acids. Avicenna J. Med. Biotechnol. 2018, 115, 115.

34. Pilone, M.S. D-Amino acid oxidase: New findings. Cell. Mol. Life Sci. 2000, 57, 1732–1747. [PubMed] [CrossRef]

35. Pollegioni, L.; Piubelli, L.; Sacchi, S.; Pilone, M.S.; Molla, G. Physiological functions of D-amino acid oxidases: From yeast to humans. Cell. Mol. Life Sci. 2007, 64, 1373–1394. [CrossRef]

36. Arnold, G.; Liscum, L.; Holtzman, E. Ultrastructural localization of D-amino acid oxidase in microperoxisomes of the rat nervous system. J. Histochem. Cytochem. 1979, 27, 735–745. [CrossRef]

37. Neims, A.H.; Zieverink, W.D.; Smilack, J.D. Distribution of D-amino acid oxidase in bovine and human nervous tissues. J. Neurochem. 1966, 13, 163–168. [CrossRef]

38. Horiike, K.; Tojo, H.; Arai, R.; Nozaki, M.; Maeda, T. D-amino-acid oxidase is confined to the lower brain stem and cerebellum in rat brain: Regional differentiation of astrocytes. Brain Res. 1994, 652, 297–303. [CrossRef]

39. Schell, M.J.; Molliver, M.E.; Snyder, S.H. D-serine, an endogenous synaptic modulator: Localization to astrocytes and glutamate-stimulated release. Proc. Natl. Acad. Sci. USA 1995, 92, 3948–3952. [CrossRef]

40. Verrall, L.; Walker, M.; Rawlings, N.; Benzle, I.; Kew, J.N.; Harrison, P.J.; Burnet, P.W. d-Amino acid oxidase and serine racemase in human brain: Normal distribution and altered expression in schizophrenia. Eur. J. Neurosci. 2007, 26, 1657–1669. [CrossRef]

41. Yoshikawa, M.; Oka, T.; Kawaguchi, M.; Hashimoto, A. MK-801 upregulates the expression of d-amino acid oxidase mRNA in rat brain. Brain Res. Mol. Brain Res. 2004, 131, 141–144. [CrossRef]

42. Horiike, K.; Tojo, H.; Arai, R.; Yamano, T.; Nozaki, M.; Maeda, T. Localization of D-amino acid oxidase in Bergmann glial cells and astrocytes of rat cerebellum. Brain Res. Bull. 1987, 19, 587–596. [CrossRef]

43. Moreno, S.; Nardacci, R.; Cimini, A.; Ceru, M.P. Immunocytochemical localization of D-amino acid oxidase in rat brain. J. Neurocytol. 1999, 28, 169–185. [CrossRef] [PubMed]

44. Sacchi, S.; Bernasconi, M.; Martineau, M.; Moothet, J.P.; Ruzzene, M.; Pilone, M.S.; Pollegioni, L.; Molla, G. pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: Effect on schizophrenia susceptibility. J. Biol. Chem. 2008, 283, 22244–22256. [CrossRef] [PubMed]
73. Nuzzo, T.; Miroballi, M.; Casamassa, A.; Mancini, A.; Gaetani, L.; Nistico, R.; Eusebi, P.; Katane, M.; Homma, H.; Calabresi, P.; et al. Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer’s disease. *Biochim. Biophys. Acta Proteins Proteom.* 2020, 1868, 140537. [CrossRef] [PubMed]

74. Biemans, E.A.; Verhoeven-Duif, N.M.; Gerrits, J.; Claassen, J.A.; Kuiperij, H.B.; Verbeek, M.M. CSF d-serine concentrations are similar in Alzheimer’s disease, other dementias, and elderly controls. *Neurobiol. Aging* 2016, 42, 213–216. [CrossRef] [PubMed]

75. Chang, C.H.; Kuo, H.L.; Ma, W.F.; Tsai, H.C. Cerebrospinal Fluid and Serum d-Serine Levels in Patients with Alzheimer’s Disease: A Systematic Review and Meta-Analysis. *J. Clin. Med.* 2020, 9, 3840. [CrossRef] [PubMed]

76. Man, E.H.; Sandhouse, M.E.; Burg, J.; Fisher, G.H. Accumulation of D-aspartic acid with age in the human brain. *Science* 1983, 220, 1407–1408. [CrossRef] [PubMed]

77. Fisher, G.H.; D’Aniello, A.; Vetere, A.; Padula, L.; Cusano, G.P.; Man, E.H. Free D-aspartate and D-alanine in normal and Alzheimer brain. *Brain Res. Bull.* 1991, 26, 983–985. [CrossRef]

78. Fisher, G.H.; D’Aniello, A.; Vetere, A.; Cusano, G.P.; Chavez, M.; Petrucelli, L. Quantification of D-aspartate in normal and Alzheimer brains. *Neurosci. Lett.* 1992, 143, 215–218. [CrossRef]

79. Fisher, G.H.; Petrucelli, L.; Gardner, C.; Emory, C.; Frey, W.H.; 2nd; Amaducci, L.; Sorbi, S.; Sorrentino, G.; Borghii, M.; D’Aniello, A. Free D-amino acids in human cerebrospinal fluid of Alzheimer disease, multiple sclerosis, and healthy control subjects. *Mol. Chem. Neupathol.* 1994, 23, 115–124. [CrossRef] [PubMed]

80. Fisher, G.; Lorenzo, N.; Abe, H.; Fujita, E.; Frey, W.H.; Emory, C.; Di Fiore, M.M.; D’Aniello, A. Free D- and L-amino acids in ventricular cerebrospinal fluid from Alzheimer and normal subjects. *Amino Acids* 1998, 15, 263–269. [CrossRef]

81. D’Aniello, A.; Vetere, A.; Fisher, G.H.; Cusano, G.; Chavez, M.; Petrucelli, L. Presence of D-alanine in proteins of normal and Alzheimer human brain. *Brain Res.* 1992, 592, 44–48. [CrossRef]

82. Lin, C.H.; Yang, H.T.; Lane, H.Y. D-glutamate, D-serine, and D-alanine differ in their roles in cognitive decline in patients with Alzheimer’s disease or mild cognitive impairment. *Pharmacolet. Biochem. Behav.* 2019, 185, 172760. [CrossRef] [PubMed]

83. Chang, C.H.; Lin, C.H.; Liu, C.Y.; Huang, C.S.; Chen, S.J.; Lin, W.C.; Yang, H.T.; Lane, H.Y. Plasma d-glutamate levels for detecting mild cognitive impairment and Alzheimer’s disease: Machine learning approaches. *J. Psychopharmacology.* 2021, 35, 265–272. [CrossRef] [PubMed]

84. Wong, D.; Atiya, S.; Fogarty, J.; Montero-Odasso, M.; Pasternak, S.H.; Brymer, C.; Borrie, M.J.; Bartha, R. Reduced Hippocampal Glutamate and Posterior Cingulate N-Acetyl Aspartate in Mild Cognitive Impairment and Alzheimer’s Disease Is Associated with Episodic Memory Performance and White Matter Integrity in the Cingulum: A Pilot Study. *J. Alzheimers Dis.* 2020, 73, 1385–1405. [CrossRef] [PubMed]

85. Vijayakumari, A.A.; Menon, R.N.; Thomas, B.; Arun, T.M.; Nandini, M.; Kesavadas, C. Glutamatergic response to a low load working memory paradigm in the left dorsolateral prefrontal cortex in patients with mild cognitive impairment: A functional magnetic resonance spectroscopy study. *Brain Imaging Behav.* 2020, 14, 451–459. [CrossRef]

86. Chen, Y.C.; Chou, W.H.; Tsou, H.H.; Fang, C.P.; Liu, T.H.; Hsu, W.C.; Wang, Y.C.; Chiou, Y.; Liu, Y.L. A Post-hoc Study of the Amino Acids in Cerebrospinal Fluid and Serum of Drug Naive Schizophrenic Patients. *Neurosci. Lett.* 2020, 719–727. [CrossRef] [PubMed]

87. Ploux, E.; Bouet, V.; Radzishhevsky, I.; Wolosker, H.; Freret, T.; Billard, J.M. Serine Racemase Deletion Affects the Excitatory/Inhibitory Balance of the Hippocampal CA1 Network. *Int. J. Mol. Sci.* 2020, 21, 9447. [CrossRef] [PubMed]

88. Coyle, J.T.; Tsai, G.E.; Ma, C.L.; Ehmsen, J.T.; Mustafa, A.K.; Han, L.; Jiang, Z.I.; Benneyworth, M.A.; Froimowitz, M.P.; Lange, N.; et al. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. *Mol. Psychiatry* 2009, 14, 719–727. [CrossRef]

89. Ploux, E.; Bouet, V.; Radzishhevsky, I.; Wolosker, H.; Freret, T.; Billard, J.M. Serine Racemase Deletion Affects the Excitatory/Inhibitory Balance of the Hippocampal CA1 Network. *Int. J. Mol. Sci.* 2020, 21, 9447. [CrossRef] [PubMed]

90. Coyle, J.T.; Basu, A.; Benneyworth, M.; Balu, D.; Konopaske, G. Glutamatergic synaptic dysregulation in schizophrenia: Therapeutic implications. In *Handbook of Experimental Pharmacology*; Springer: Berlin, Heidelberg, 2012; pp. 267–295.

91. Basu, A.C.; Tsai, G.E.; Ma, C.L.; Ehmsen, J.T.; Mustafa, A.K.; Han, L.; Jiang, Z.I.; Benneyworth, M.A.; Froimowitz, M.P.; Lange, N.; et al. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. *Mol. Psychiatry* 2009, 14, 719–727. [CrossRef]

92. Ploux, E.; Bouet, V.; Radzishhevsky, I.; Wolosker, H.; Freret, T.; Billard, J.M. Serine Racemase Deletion Affects the Excitatory/Inhibitory Balance of the Hippocampal CA1 Network. *Int. J. Mol. Sci.* 2020, 21, 9447. [CrossRef] [PubMed]

93. Coyle, J.T.; Basu, A.; Benneyworth, M.; Balu, D.; Konopaske, G. Glutamatergic synaptic dysregulation in schizophrenia: Therapeutic implications. In *Handbook of Experimental Pharmacology*; Springer: Berlin, Heidelberg, 2012; pp. 267–295.

94. Coyle, J.T.; Tsai, G.; Goff, D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. *Ann. N. Y. Acad. Sci.* 2003, 1003, 318–327. [CrossRef]

95. Balu, D.T. The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment. *Adv. Pharmacol.* 2016, 76, 351–382.

96. Bendikov, I.; Nadri, C.; Amar, S.; Panizzuttii, R.; De Miranda, J.; Wolosker, H.; Agam, G. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. *Schizophr. Res.* 2007, 90, 41–51. [CrossRef]

97. Hashimoto, K.; Engberg, G.; Shimizu, E.; Nordin, C.; Lindstrom, L.H.; Iyo, M. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 2005, 29, 767–769. [CrossRef] [PubMed]
98. Fuchs, S.A.; De Barse, M.M.; Scheepers, F.E.; Cahn, W.; Dorland, L.; de Sain-van der Velden, M.G.; Klomp, L.W.; Berger, R.; Kahn, R.S.; de Koning, T.J. Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients. Eur. Neuropsychopharmacol. 2008, 18, 333–338. [CrossRef]

99. Hashimoto, K.; Fukushima, T.; Shimizu, E.; Komatsu, N.; Watanabe, H.; Shinoda, N.; Nakazato, M.; Kumakiri, C.; Okada, S.; Hasegawa, H.; et al. Decreased serum levels of D-serine in patients with schizophrenia: Evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003, 60, 572–576. [CrossRef]

100. Calcia, M.A.; Madeira, C.; Alheira, F.V.; Silva, T.C.; Tannos, F.M.; Vargas-Lopes, C.; Goldenstein, N.; Brasil, M.A.; Ferreira, S.T.; Panizzutti, R. Plasma levels of D-serine in Brazilian individuals with schizophrenia. Schizophr. Res. 2012, 142, 83–87. [CrossRef]

101. Cho, S.E.; Na, K.S.; Cho, S.J.; Kang, S.G. Low d-serine levels in schizophrenia: A systematic review and meta-analysis.Neurosci. Lett. 2016, 634, 42–51. [CrossRef]

102. Dyakin, V.V.; Wisniewski, T.M.; Latjha, A. Chiral Interface of Amyloid Beta (Abeta): Relevance to Protein Aging, Aggregation and Neurodegeneration. Symmetry 2020, 12, 585. [CrossRef] [PubMed]

103. Kaneko, I.; Morimoto, K.; Kubo, T. Drastic neuronal loss in vivo by beta-amyloid racemized at Ser(26) residue: Conversion of non-toxic [D-Ser(26)] beta-amyloid 1-40 to toxic and proteinase-resistant fragments. Neuroscience 2001, 104, 1003–1011. [CrossRef]

104. Kubo, T.; Kumagae, Y.; Miller, C.A.; Kaneko, I. Beta-amyloid racemized at the Ser26 residue in the brains of patients with Alzheimer disease: Implications in the pathogenesis of Alzheimer disease. J. Neuropathol. Exp. Neurol. 2003, 62, 248–259. [CrossRef] [PubMed]

105. Chung, J.K.; Nakajima, S.; Plitman, E.; Iwata, Y.; Uy, D.; Gerretsen, P.; Caravaggio, F.; Chakravarty, M.M.; Graff-Guerrero, A. Chiral Interface of Amyloid Beta (Abeta): Relevance to Protein Aging, Aggregation and Neurodegeneration. Symmetry 2020, 12, 585. [CrossRef] [PubMed]

106. Ohnuma, T.; Sakai, Y.; Maeshima, H.; Hatano, T.; Hanzawa, R.; Abe, S.; Kida, S.; Shibata, N.; Suzuki, T.; Ariai, H. Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: Results from the Juntendo University Schizophrenia Projects (JUSP). Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 1905–1912. [CrossRef] [PubMed]

107. Tsai, G.; Yang, P.; Chung, L.C.; Lange, N.; Coyle, J.T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 1999, 44, 1081–1089. [CrossRef] [PubMed]

108. Madeira, C.; Freitas, M.E.; Vargas-Lopes, C.; Wolosker, H.; Panizzutti, R. Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr. Res. 2008, 101, 76–83. [CrossRef] [PubMed]

109. Kapoor, R.; Lim, K.S.; Cheng, A.; Garrick, T.; Kapoor, V. Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1). Brain Res. 2006, 1106, 205–210. [CrossRef] [PubMed]

110. Burnet, P.W.; Eastwood, S.L.; Bristow, G.C.; Godlewska, B.R.; Sikka, P.; Walker, M.; Harrison, P.J. D-amino acid oxidase activity and expression are increased in schizophrenia. Mol. Psychiatry 2008, 13, 658–660. [CrossRef]

111. Errico, F.; Napolitano, F.; Squailia, M.; Vitucci, D.; Blasi, G.; de Bartolomeis, A.; Bertolino, A.; D’Aniello, A.; Uusiolo, A.; D’Aniello, A. Increased brain D-serine levels in patients with schizophrenia as their clinical symptoms improve: Results from the Juntendo University Schizophrenia Projects (JUSP). Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 1905–1912. [CrossRef] [PubMed]

112. Hashimoto, A.; Fukushima, S.; Nishikawa, T.; Oka, T.; Takahashi, K.; Mito, T.; Takashima, S.; Doi, N.; Mizutani, Y.; Yamaizaki, T.; et al. Embryonic development and postnatal changes in free D-aspartate and D-serine in the human prefrontal cortex. J. Neurochem. 1993, 61, 348–351. [CrossRef]

113. Wolosker, H.; D’Aniello, A.; Snyder, S.H. D-aspartate disposition in neuronal and endocrine tissues: Ontogeny, biosynthesis and release. Neuroscience 2000, 100, 183–189. [CrossRef]

114. Van Veldhoven, P.P.; Brees, C.; Mannnaerts, G.P. D-aspartate oxidase, a peroxisomal enzyme in liver of rat and man. Biochim. Biophys. Acta 1991, 1073, 203–208. [CrossRef]

115. Wolosker, H.; D’Aniello, A.; Snyder, S.H. D-aspartate disposition in neuronal and endocrine tissues: Ontogeny, biosynthesis and release. Neuroscience 2000, 100, 183–189. [CrossRef]

116. Errico, F.; D’Argerio, V.; Sforazzini, F.; Iasevoli, F.; Squailia, M.; Guerri, G.; Napolitano, F.; Angriano, D.; Di Maio, A.; Keller, S.; et al. A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice. Transl. Psychiatry 2015, 5, e512. [CrossRef] [PubMed]

117. Hashimoto, K.; Fukushima, T.; Shimizu, E.; Komatsu, N.; Watanabe, H.; Shinoda, N.; Nakazato, M.; Kumakiri, C.; Okada, S.; Hasegawa, H.; et al. Decreased serum levels of D-serine in patients with schizophrenia: Evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003, 60, 572–576. [CrossRef]

118. Nuzzo, T.; Sacchi, S.; Alheira, F.V.; Silva, T.C.; Tannos, F.M.; Vargas-Lopes, C.; Goldenstein, N.; Brasil, M.A.; Ferreira, S.T.; Panizzutti, R. Plasma levels of D-serine in Brazilian individuals with schizophrenia. Schizophr. Res. 2012, 142, 83–87. [CrossRef]

119. Keller, S.; Punzo, D.; Cuomo, M.; Affinito, O.; Coretti, L.; Sacchi, S.; Florio, E.; Lembo, F.; Carella, M.; Copetti, M.; et al. Decreased free D-aspartate levels are linked to enhanced D-aspartate oxidase activity in the dorsolateral prefrontal cortex of schizophrenia patients. NPJ Schizophr. 2017, 3, 16. [CrossRef] [PubMed]

120. Nuzzo, T.; Feligioni, M.; Cristino, L.; Pagano, I.; Marcelli, S.; Iannuzzi, F.; Imperatore, R.; D’Angelo, L.; Petrella, C.; Carella, M.; et al. Free d-aspartate triggers NMDA receptor-dependent cell death in primary cortical neurons and perturbs JNK activation, Tau phosphorylation, and protein SUMoylation in the cerebral cortex of mice lacking d-aspartate oxidase activity. Exp. Neurol. 2019, 317, 51–65. [CrossRef]

121. Keller, S.; Punzo, D.; Cuomo, M.; Affinito, O.; Coretti, L.; Sacchi, S.; Florio, E.; Lembo, F.; Carella, M.; Copetti, M.; et al. Decreased free D-aspartate levels are linked to enhanced D-aspartate oxidase activity in the dorsolateral prefrontal cortex of schizophrenia patients. NPJ Schizophr. 2017, 3, 16. [CrossRef] [PubMed]

122. Nuzzo, T.; Feligioni, M.; Cristino, L.; Pagano, I.; Marcelli, S.; Iannuzzi, F.; Imperatore, R.; D’Angelo, L.; Petrella, C.; Carella, M.; et al. Free d-aspartate triggers NMDA receptor-dependent cell death in primary cortical neurons and perturbs JNK activation, Tau phosphorylation, and protein SUMoylation in the cerebral cortex of mice lacking d-aspartate oxidase activity. Exp. Neurol. 2019, 317, 51–65. [CrossRef] [PubMed]
120. Errico, F.; Nuzzo, T.; Carella, M.; Bertolino, A.; Usiello, A. The Emerging Role of Altered d-Aspartate Metabolism in Schizophrenia: New Insights From Preclinical Models and Human Studies. Front. Psychiatry 2018, 9, 559. [CrossRef]

121. Tortorella, A.; Monteleone, P.; Fabbruzzo, M.; Viggiano, A.; De Luca, L.; Maj, M. Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychopharmacology 2001, 44, 167–171. [CrossRef]

122. De Luca, V.; Viggiano, E.; Messina, G.; Viggiano, A.; Borlido, C.; Viggiano, A.; Mondi, M. Peripheral amino Acid levels in schizophrenia and antipsychotic treatment. Psychiatry Invest. 2008, 5, 203–208. [CrossRef]

123. Davison, J.; O’Gorman, A.; Brennan, L.; Cotter, D.R. A systematic review of metabolite biomarkers of schizophrenia. Schizophr. Res. 2018, 195, 32–50. [CrossRef] [PubMed]

124. Saleem, S.; Shaukat, F.; Gul, A.; Arooj, M.; Malik, A. Potential role of amino acids in pathogenesis of schizophrenia. Int. J. Health Sci. 2017, 11, 63–68.

125. Shulman, Y.; Grant, S.; Seres, P.; Harstock, C.; Baker, G.; Tibbo, P. The relation between peripheral and central glutamate and glutamine in healthy male volunteers. J. Psychiatry Neuropsychiatry. 2006, 31, 406–410. [PubMed]

126. Takahashi, S.; Kakuuchi, T.; Fuji, K.; Kera, Y.; Yamada, R.H. Physiological role of D-aspartate oxidase in the assimilation and detoxification of D-aspartate in the yeast Cryptococcus hemicola. Yeast 2005, 22, 1203–1212. [CrossRef] [PubMed]

127. Han, H.; Miyoshi, Y.; Koga, R.; Mita, M.; Konno, R.; Hamase, K. Changes in D-aspartic acid and D-glutamic acid levels in the tissues and physiological fluids of mice with various D-aspartate oxidase activities. J. Pharm. Biomed. Anal. 2015, 116, 47–52. [CrossRef]

128. Ariyoshi, M.; Katane, M.; Hamase, K.; Miyoshi, Y.; Nakane, M.; Hoshino, A.; Okawa, Y.; Mita, Y.; Kaimoto, S.; Uchihashi, M.; et al. D- Glutamate is metabolized in the heart mitochondria. Sci. Rep. 2017, 7, 43911. [CrossRef]

129. Labrie, V.; Fukumura, R.; Rastogi, A.; Fick, L.J.; Wang, W.; Boutros, P.C.; Kennedy, J.L.; Semeralul, M.O.; Lee, F.H.; Baker, G.B.; et al. Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum. Mol. Genet. 2009, 18, 3227–3243. [CrossRef]

130. Balu, D.T.; Li, Y.; Puhl, M.D.; Benneyworth, M.A.; Basu, A.C.; Takagi, S.; Bolshakov, V.Y.; Coyle, J.T. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc. Natl. Acad. Sci. USA 2013, 110, E2400–E2409. [CrossRef]

131. Puhl, M.D.; Mintzopoulos, D.; Jensen, J.E.; Gillis, T.E.; Konopaske, G.T.; Kaufman, M.J.; Coyle, J.T. In vivo magnetic resonance imaging of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion. Hum. Mol. Genet. 2019, 38, 557–567. [CrossRef]

132. Jacobi, A.A.; Halawani, S.; Lynch, D.R.; Lin, H. Neuronal serine racemase associates with Disrupted-In-Schizophrenia-1 and DISC1 agglomerates: Implications for schizophrenia. Neurosci. Lett. 2019, 692, 107–114. [CrossRef] [PubMed]

133. Morita, Y.; Ujike, H.; Tanaka, Y.; Otani, K.; Kishimoto, M.; Morio, A.; Konno, K.; Okahisa, Y.; Matsushita, M.; Morikawa, A.; et al. A genetic variant of the serine racemase gene is associated with schizophrenia. Biol. Psychiatry 2007, 61, 1200–1203. [CrossRef] [PubMed]

134. Shizheng, A.; Rettke, B. The Development of New Drugs for Schizophrenia Treatment. Front. Mol. Neurosci. 2018, 11, 175–183. [CrossRef]

135. Saleem, S.; Cappelletti, P.; Pirone, L.; Smaldone, G.; Pedone, E.; Pollegioni, L. Elucidating the role of the pLG72 R30K substitution in schizophrenia susceptibility. FEBS Lett. 2017, 591, 646–655. [CrossRef] [PubMed]

136. Caldicinelli, L.; Molla, G.; Bracci, L.; Lelli, B.; Pileri, S.; Cappelletti, P.; Sacchi, S.; Pollegioni, L. Effect of ligand binding on human D-amino acid oxidase: Implications for the development of new drugs for schizophrenia treatment. Protein Sci. 2010, 19, 1500–1512. [CrossRef] [PubMed]

137. Jagannath, V.; Brotzakis, Z.E.; Parrinello, M.; Walitza, S.; Grunblatt, E. Controversial Effects of D-Amino Acid Oxidase Activator (DAOA)/G72 on D-Amino Acid Oxidase (DAO) Activity in Human Neuronal, Astrocyte and Kidney Cell Lines: The N-methyl D-aspartate (NMDA) Receptor Hypofunction Hypothesis. Front. Mol. Neurosci. 2017, 10, 342. [CrossRef]
168. Velez, J.I.; Chandrasekharappa, S.C.; Henao, E.; Martinez, A.F.; Harper, U.; Jones, M.; Solomon, B.D.; Lopez, L.; Garcia, G.; Aguirre-Acevedo, D.C.; et al. Pooling/bootstrap-based GWAS (pbGWAS) identifies new loci modifying the age of onset in PSEN1 p.Glu280Ala Alzheimer’s disease. Mol. Psychiatry 2013, 18, 568–575. [CrossRef] [PubMed]

169. Velez, J.I.; Rivera, D.; Mastromaridi, C.A.; Patel, H.R.; Tobon, C.; Villegas, A.; Cai, Y.; Eastal, S.; Loper, F.; Arcos-Burgos, M. A Mutation in DAOA Modifies the Age of Onset in PSEN1 E280A Alzheimer’s Disease. Neuronal Plast. 2016, 2016, 9760314. [CrossRef]

170. Schumacher, J.; Abou Jamra, R.; Becker, T.; Klokpp, N.; Franke, P.; Jacob, C.; Sand, P.; Fritze, J.; Ohlraun, S.; Schulze, T.G.; et al. Investigation of the DAOA/G30 locus in panic disorder. Mol. Psychiatry 2005, 10, 428–429. [CrossRef] [PubMed]

171. Schulze, T.G.; Ohlraun, S.; Czerski, P.M.; Schumacher, J.; Kassm, L.; Descher, M.; Gross, M.; Tullius, M.; Heidmann, V.; Kovalenko, S.; et al. Genotype-phenotype studies in bipolar disorder showing association between the DAOA/G30 locus and persecutory delusions: A first step toward a molecular genetic classification of psychiatric phenotypes. Am. J. Psychiatry 2005, 162, 2101–2108. [CrossRef]

172. Hartz, S.M.; Ho, B.C.; Andreasen, N.C.; Librant, A.; Rudd, D.; Epping, E.A.; Wassink, T.H. G72 influences longitudinal change in schizophrenia. World J. Biol. Psychiatry 2017, 19, 357–368. [CrossRef] [PubMed]

173. Jagannath, V.; Marinova, Z.; Monoranu, C.M.; Walitza, S.; Grunblatt, E. Expression of D-Amino Acid Oxidase (DAO/DAAO) receptors via co-agonist site: An fMRI study in the rat brain. Neurosci. Lett. 2005, 380, 111–115. [CrossRef] [PubMed]

174. Panizzutti, R. Effects of low-dose D-serine on recognition and working memory in mice. Psychopharmacology 2011, 218, 461–470. [CrossRef]

175. Shimazaki, T.; Kaku, A.; Chaki, S. D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Front. Neurosci. 2017, 11, 31. [CrossRef] [PubMed]

176. Bado, P.; Madeira, C.; Vargas-Lopes, C.; Moulin, T.C.; Wasilewska-Sampaio, A.P.; Maretti, L.; de Oliveira, R.V.; Amaral, O.B.; Kovalenko, S.; et al. Genotype-phenotype studies in bipolar disorder showing association between the DAOA/G30 locus and persecutory delusions: A first step toward a molecular genetic classification of psychiatric phenotypes. Am. J. Psychiatry 2005, 162, 2101–2108. [CrossRef]

177. Schumacher, J.; Abou Jamra, R.; Becker, T.; Klokpp, N.; Franke, P.; Jacob, C.; Sand, P.; Fritze, J.; Ohlraun, S.; Schulze, T.G.; et al. Investigation of the DAOA/G30 locus in panic disorder. Mol. Psychiatry 2005, 10, 428–429. [CrossRef] [PubMed]

178. Matsui, T.; Sekiguchi, M.; Hashimoto, A.; Tomita, U.; Nishikawa, T.; Wada, K. Functional comparison of D-serine and glycine in motoneuron degeneration through D-serine. Proc. Natl. Acad. Sci. USA 2012, 109, 627–632. [CrossRef] [PubMed]
191. Bartlett, G.R. The inhibition of d-amino acid oxidase by benzoic acid and various monosubstituted benzoic acid derivatives. *J. Am. Chem. Soc.* 1948, 70, 1010. [CrossRef]

192. Moses, J.; Siddiqui, A.; Silverman, P.B. Sodium benzoate differentially blocks circling induced by D- and L-dopa in the hemi-parkinsonian rat. *Neurosci. Lett.* 1996, 218, 145–148. [CrossRef]

193. Williams, R.E.; Lock, E.A. Sodium benzoate attenuates D-serine induced nephrotoxicity in the rat. *Toxicology* 2005, 207, 35–48. [CrossRef]

194. Modi, K.K.; Roy, A.; Brahmachari, S.; Rangasamy, S.B.; Pahan, K. Cinnamon and Its Metabolite Sodium Benzoate Attenuate the Activation of p21rac and Protect Memory and Learning in an Animal Model of Alzheimer’s Disease. *PLoS ONE* 2015, 10, e0130398. [CrossRef] [PubMed]

195. Lin, C.H.; Chen, P.K.; Wang, S.H.; Lane, H.Y. Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial. *J. Psychopharmacol.* 2019, 33, 1030–1033. [CrossRef] [PubMed]

196. Lin, C.H.; Chen, P.K.; Wang, S.H.; Lane, H.Y. Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia: Secondary Analysis of a Randomized Clinical Trial. *JAMA Netw. Open* 2021, 4, e216156. [CrossRef]

197. Nimmo, J.T.; Kelly, L.; Verma, A.; Carare, R.O.; Nicoll, J.A.R.; Dodart, J.C. Amyloid-beta and alpha-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials. *Front. Neurosci.* 2021, 15, 733857. [CrossRef] [PubMed]

198. Sevigny, J.; Chiao, P.; Bussiere, T.; Weinreb, P.H.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y.; et al. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. *Nature* 2016, 537, 50–56. [CrossRef] [PubMed]